1)Jones RB, et al:Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis;A randomised, non-inferiority trial. Ann Rheum Dis 78:399-405, 2019
2)Jayne D, et al:Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis;A randomized controlled study. Arthritis Rheumatol 71:952-963, 2019
3)Charles P, et al:Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission;Results of a multicentre, randomised controlled, phase Ⅲ trial(MAINRITSAN2). Ann Rheum Dis 77:1143-1149, 2018
4)Walsh M, et al:The effects of plasma exchange and reduced-dose glucocorticoids during remission-induction for treatment of severe ANCA-associated vasculitis. 2018 https://acrabstracts.org/abstract/the-effects-of-plasma-exchange-and-reduced-dose-glucocorticoids-during-remission-induction-for-treatment-of-severe-anca-associated-vasculitis(2020年2月閲覧)
5)Walsh M, et al:Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis(PEXIVAS);Protocol for a randomized controlled trial. Trials 14:73, 2013
6)Green H, et al:Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients;Systematic review and meta-analysis of randomized controlled trials. Mayo Clinic Proceedings 82:1052-1059, 2007
7)骨粗鬆症の予防と治療ガイドライン作成員会(編):骨粗鬆症の予防と治療ガイドライン2015年版.ライフサイエンス出版,2015